Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

Reduction or Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)

A legfontosabb adatok

Ki végzi
InnovHeart
Hol
Los Angeles, New York, Portland, Sacramento és Thousand Oaks (Egyesült Államok)Mind a 5 helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
15 fő, tervezett
Kezdés
2026. aug. 5.
Várható befejezés
2032. szept.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Mitral Valve Replacement
A regiszteradat frissítve
2026. augusztus 10.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 50 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 18 years or older
  • Symptomatic, moderate to severe or severe, functional or mixed, mitral regurgitation (≥ Grade 3+)
  • NYHA functional Class ≥ II. If Class IV, patient must be ambulatory
  • Ability to tolerate oral anticoagulation
  • Ability to qualify for bailout surgery (which may include open heart surgery)
  • High risk for open-heart mitral valve surgery due to age, co-morbidities or frailty, as determined by the Heart Team
  • Willing and able to complete study-related assessments and questionnaires

Ki nem vehet részt

  • Endocarditis in the 3 months prior to procedure date
  • COPD on home oxygen therapy deemed too high risk for intubation
  • Myocardial infarction during prior 30 days
  • Stroke or TIA during prior 90 days
  • Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed)
  • Prior mitral valve treatment (e.g., valve repair or replacement, MitraClip, etc.), and/or anticipated mitral valve treatment prior to enrollment
  • Prior surgical mechanical valve AVR
  • Prior TAVI. -Need for any planned cardiovascular surgery or intervention (other than for MV disease) within 30 days post-index procedure
  • CRT, CRT-D, IPG or ICD implanted in previous 30 days
  • Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure <90mmHg, Inotropic dependent or IABP/mechanical circulatory support; CABG or PCI within previous 30 days
  • Prior or planned heart transplantation (UNOS status 1)
  • Excessive frailty or comorbid conditions that preclude the anticipated benefit of the mitral valve replacement
  • Life expectancy <1 yr. due to noncardiac conditions
  • Current admission with acute heart failure exacerbation
  • Active systemic infection
  • Severe pulmonary arterial hypertension (PAH), defined as PASP > 70mmHg
  • Documented bleeding or coagulation disorders (hypo- or hyper-coagulable states)
  • Severe connective tissue disease under chronic immunosuppressive or cortisone therapy
  • Inadequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure, as reviewed by the Patient Screening Committee
  • Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or other structural heart disease causing heart failure with the exception of dilated ischemic or non-ischemic cardiomyopathy; Procedural Exclusion Criteria
  • Known hypersensitivity or contraindication to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy)
  • Documented hypersensitivity to nickel or titanium; Cardiac Imaging Exclusion Criteria (evaluated by Core Labs)
  • Chronic renal failure defined as eGFR < 30 mL/min/m2 or on renal replacement therapy
  • Platelets < 90,000
  • Purely degenerative (organic/primary) (i.e. intrinsic valve lesions) mitral regurgitation
  • Dependency on inotropic agents or mechanical circulatory support
  • Untreated clinically significant CAD
  • Modified Rankin Scale ≥4 disability
  • Refuses blood transfusions
  • Participating in other investigational studies likely to confound the results or affect the study
  • Unable or does not sign the study informed consent form
  • Patients classified as "vulnerable patients"; Cardiovascular Exclusion Criteria
  • Physical evidence of right-sided CHF:; Patients with ascites; Patients with anasarca (generalized edema / hydropsy)
  • Contraindications to TEE imaging
  • Left ventricular EF ≤ 30% by echocardiogram
  • Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass
  • Extensive mitral flail leaflets
  • Evidence of new or untreated intracardiac thrombus, mass, or vegetation
  • Severe right ventricular dysfunction
  • Severe tricuspid regurgitation
  • Hemodynamically significant inter-atrial shunt (ASD)
  • Severe aortic regurgitation or aortic stenosis
  • Anatomic ineligibility for SATURN Valve or SATURN TS procedure as determined by the Screening Committee

Helyszínek itt: Egyesült Államok

  • Cedars-Sinai Medical CenterLos Angeles, Egyesült ÁllamokContact: Mitch GheorghiuToborzás még nem indult
  • Columbia University Irving Medical Center/New York Presbyterian HospitalNew York, Egyesült ÁllamokContact: Treena WilliamsRésztvevőt keres
  • Oregon Health Science UniversityPortland, Egyesült ÁllamokContact: Amy KoskiToborzás még nem indult
  • UC Davis HealthSacramento, Egyesült ÁllamokContact: Kaelyn Tuerner-LeeToborzás még nem indult
  • Los Robles Regional Medical CenterThousand Oaks, Egyesült ÁllamokContact: Reas SolomonRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

CASSINI-US is a prospective, single-arm, multicenter early feasibility study enrolling up to 15 patients at up to 5 sites in the United States (US).

A teljes eredeti leírásKevesebb

The purpose of the study is to evaluate the technical (implant) feasibility, and safety, and performance of the SATURN TS TMVR System for the treatment of moderate-severe or severe, symptomatic mitral regurgitation through a transcatheter approach.

Primary objectives evaluate the implant feasibility, and acute safety and performance of the SATURN TS TMVR System. The secondary objective and additional outcome measures characterize the long-term safety and performance of the SATURN TS TMVR System.

A vizsgálat csoportja

  • SATURN TMVR CohortA vizsgált kezelés

    Saturn transseptal TMVR System implant

    Kezelés: Mitral Valve Replacement

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Reduction or Elimination of Mitral Regurgitation With the SATURN Trans-septal TMVR System in Patients With Severe, Symptomatic Mitral Regurgitation (Cassini-US)
A regiszteradat frissítve
2026. augusztus 10.